Search results
Recordati Shares Rise as Investors Reportedly Circle CVC Stake
US News & World Report· 3 days agoShares in Italian drugmaker Recordati rose almost 3% on Tuesday, boosted by a report that investment funds KKR and TPG had expressed preliminary interest in... Capital Partners ...
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
CNBC· 4 days agoAshkenazi, who will step in as the new CFO of Alphabet on July 31, has been key to managing the...
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Motley Fool via Yahoo Finance· 6 days agoEli Lilly's prospects hardly depend on donanemab, although it would be a nice addition to its...
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
Motley Fool via Yahoo Finance· 7 days agoLet's consider two examples: Novo Nordisk (NYSE: NVO) and Medtronic (NYSE: MDT). 1. Novo Nordisk...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 2 days agoThe PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Zacks· 3 days agoFree Report) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. This has lagged the ...
Kansas AG Kris Kobach suing Pfizer for ‘misleading Kansans on COVID vaccine’
KWCH· 4 days agoKansas Attorney General Kris Kobach announced that he’s suing Pfizer “for misleading claims it made...
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Zacks via Yahoo Finance· 6 days agoThis metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the...
Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled...
Fortune via Yahoo Finance· 4 days agoIn his remarks, Sanders also called out German pharmaceutical group Merck, another maker of diabetes...
Vanda Rejects Future Pak and Cycle Pharma's Takeover Offers
US News & World Report· 1 day agoThis is the third time Vanda has rejected a buyout offer from Future Pak. After its first offer from Future Pak in April, Vanda adopted a shareholder rights plan, known as a "poison pill", to reduce the chances of a hostile takeover.
